Stephens & Co. Initiates Coverage On Veracyte with Overweight Rating, Announces Price Target of $52
Stephens & Co. initiates coverage on Veracyte (NASDAQ:VCYT) with a Overweight rating and announces Price Target of $52.
Cathie Wood’s ARK Invest Posts Fund Purchases For Monday, Nov. 15, 2021: NTLA, TWOU, VCYT, BEAM, MTLS, PRLB, TSP, ACHR, VLD, SPLK, DIS, BFLY, SGFY, ONEM, ALLO, VERV, QSI, HOOD, DKNG, TWLO, TOST, PAG, GRMN, DDD, MKFG
Intellia Therapeutics (NTLA)
2U (TWOU)
Veracyte (VCYT)
Beam Therapeutics (BEAM)
Materialise (MTLS)
Proto Labs (PRLB)
TuSimple Holdings (TSP)
Archer Aviation (ACHR)
Velo3d (VLD)
Splunk (SPLK)
The Walt Disney
Raymond James Maintains Outperform on Veracyte, Raises Price Target to $62
Raymond James analyst Andrew Cooper maintains Veracyte (NASDAQ:VCYT) with a Outperform and raises the price target from $50 to $62.
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
Veracyte Announces Immunoscore Colon Cancer Test Included In ESMO Clinical Practice Guidelines Adapted For Pan-Asia
Veracyte, Inc. (NASDAQ:VCYT) today announced that its Immunoscore Colon Cancer test has been included in the Pan-Asian adapted ESMO1 Clinical Practice Guidelines for the diagnosis, treatment and follow-up of
Veracyte Highlights Data Presented At ASTRO 2021; Says Data Validate Prognostic Value Of Decipher Prostate Genomic Test In Newly Diagnosed, Clinically High-Risk Prostate Cancer
Veracyte, Inc. (NASDAQ:VCYT) announced today that new data being presented at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting suggest the company's Decipher Prostate genomic classifier
Veracyte Says New Data To Be Presented At ASTRO 2021; Co Says Data Further Validate Clinical Utility Of Veracyte’s Decipher Prostate Genomic Classifier
Veracyte, Inc. (NASDAQ:VCYT) announced that new data further validating the clinical utility of the company's Decipher Prostate genomic test will be presented at the American Society for Radiation Oncology
Veracyte Highlights New Data Showing Its Envisia Genomic Classifier Impacted Clinical-Decision Making In Idiopathic Pulmonary Fibrosis
Findings to be shared in oral presentation at CHEST Annual Meeting 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ:VCYT) announced new data demonstrating that the Envisia Genomic Classifier